U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H32N2O5
Molecular Weight 476.5641
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of NALFURAFINE

SMILES

[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]5(O)CC[C@H]2N(C)C(=O)\C=C\C7=COC=C7)=CC=C3O

InChI

InChIKey=XGZZHZMWIXFATA-UEZBDDGYSA-N
InChI=1S/C28H32N2O5/c1-29(23(32)7-4-18-9-13-34-16-18)20-8-10-28(33)22-14-19-5-6-21(31)25-24(19)27(28,26(20)35-25)11-12-30(22)15-17-2-3-17/h4-7,9,13,16-17,20,22,26,31,33H,2-3,8,10-12,14-15H2,1H3/b7-4+/t20-,22-,26+,27+,28-/m1/s1

HIDE SMILES / InChI

Molecular Formula C28H32N2O5
Molecular Weight 476.5641
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 1
Optical Activity UNSPECIFIED

Nalfurafine, an opioid κ-selective agonist, has been officially approved for resistant pruritus in HD patients on the basis of a well-evidenced clinical trial in Japan. Nalfurafine hydrochloride is a potent and selective agonist for mouse, rat, guinea pig, and human κ-opioid receptors without significant activity on µ- and δ-opioid receptors. Nalfurafine hydrochloride (2.5 and 5 ug/day) has been proven to be safe and effective for the treatment of HD patients with uremic pruritus resistant to antihistamines.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
REMITCH

Approved Use

Improvement of pruritus in hemodialysis patients (only for cases resistant to conventional treatments)

Launch Date

1.23249597E12
PubMed

PubMed

TitleDatePubMed
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
2005 Jan
Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in rats.
2006 Sep
TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
2009 Oct 12
Essential structure of opioid κ receptor agonist nalfurafine for binding to the κ receptor 2: synthesis of decahydro(iminoethano)phenanthrene derivatives and their pharmacologies.
2012 Aug 1
Patents

Sample Use Guides

The usual oral dosage for adults is 2.5 ug of nalfurafine hydrochloride, once a day, after supper or before sleep. The dosage may be adjusted according to symptoms provided that it does not exceed 5 ug once a day.
Route of Administration: Oral
Nalfurafine hydrochloride inhibited the electrically-induced contraction of mouse vas deferens with the IC50 of 0.080 nmol/L and 0.12 nmol/L in two independent experiments in vitro.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:14:10 UTC 2023
Edited
by admin
on Fri Dec 15 17:14:10 UTC 2023
Record UNII
XC41AVD567
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NALFURAFINE
INN   MI   WHO-DD  
INN  
Official Name English
nalfurafine [INN]
Common Name English
NALFURAFINE [MI]
Common Name English
2-PROPENAMIDE, N-((5.ALPHA.,6.BETA.)-17-(CYCLOPROPYLMETHYL)-4,5-EPOXY-3,14-DIHYDROXYMORPHINAN-6-YL)-3-(3-FURANYL)-N-METHYL-, (2E)-
Systematic Name English
Nalfurafine [WHO-DD]
Common Name English
MT-9938
Code English
Classification Tree Code System Code
NCI_THESAURUS C67413
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
WHO-VATC QV03AX02
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
WHO-ATC V03AX02
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
Code System Code Type Description
EVMPD
SUB25222
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
DRUG CENTRAL
4673
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
INN
8209
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
PUBCHEM
6445230
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
CAS
152657-84-6
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
MERCK INDEX
m7713
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY Merck Index
NCI_THESAURUS
C80585
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID70905119
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
FDA UNII
XC41AVD567
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
DRUG BANK
DB13471
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
WIKIPEDIA
Nalfurafine
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
ChEMBL
CHEMBL267495
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
SMS_ID
100000089236
Created by admin on Fri Dec 15 17:14:10 UTC 2023 , Edited by admin on Fri Dec 15 17:14:10 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY